GeneDx Holdings (WGS) shares were down over 5% in recent Wednesday trading following a Grizzly Research report alleging that the company is inflating its revenue through illegal billing practices.
The report claims GeneDx has been using a method called "code stacking" that involves billing insurers with multiple procedure codes for the same test to secure reimbursements above standard rates.
Insiders said that CEO Katherine Stueland and CFO Kevin Feeley have consistently sold shares immediately upon vesting, suggesting they might be aware of an "imminent risk," the report said. Additional allegations from the short-seller include that the company operated "independent" counselor entities to steer patients exclusively toward its testing services.
The Department of Justice is stepping up its scrutiny of billing practices in Medicare and Medicaid, with penalties already exceeding $800 million for similar fraud cases and they expect GeneDx to be next if further evidence of wrongdoing emerges, Grizzly Research said, citing industry sources.
GeneDx did not immediately respond to a request for comment from MT Newswires.
Price: 68.22, Change: -3.80, Percent Change: -5.28
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.